hBM‐MSC‐Derived EVs Improved Pulmonary Vascular Remodeling and Right Ventricle Function in a Mouse Pulmonary Hypertension Model
4 affiliations
- 1Department of Surgery, Rhode Island Hospital Cardiovascular Research Center, Division of Cardiothoracic Surgery Providence Rhode Island USA
- 2The Warren Alpert Medical School of Brown University Providence Rhode Island USA
- 3Division of Hematology/Oncology, Department of Medicine Rhode Island Hospital Providence Rhode Island USA
- 4Cardiovascular Physiology Laboratory, Department of Physiology Institute of Basic Health Sciences, UFRGS Porto Alegre Brazil
Abstract
Pulmonary hypertension (PH) is characterized by elevated mean pulmonary arterial pressure (mPAP), pulmonary vascular remodeling, and right ventricle (RV) hypertrophy and failure. PH is a rare disease, with significant morbidity and limited therapeutic options. Human Mesenchymal Stem‐cell derived (hMSC) extracellular vesicles (EVs) have shown potential in improving pulmonary artery flow and RV function. The aim of this study was to evaluate the therapeutic effects of hMSC‐EVs in a mouse model of monocrotaline (MCT)‐induced PH. MCT + EVs animals compared to MCT + vehicle alone demonstrated improvement in RV function with an increase in Tricuspid Annular Plane Systolic Excursion by 37.1 ± 2.6% (p = 0.0011) and reduction in RV hypertrophy by 18.6 ± 7.6% (p = 0.0218) using Fulton's index. Pulmonary artery flow, evaluated by echocardiography of pulmonary artery acceleration time, was improved with EV treatment by 18.5 ± 1.3% (p = 0.0419). Histological studies demonstrated a corresponding reduction in pulmonary arteriolar muscularization by 41.2 ± 18.5% (p = 0.0004). Western blot analysis of MCT + EVs versus MCT + vehicle demonstrated modulations in proteins related to metabolism and cellular energetics in lungs and to calcium sequestration in RV. Proteomic analysis of circulating EVs from MCT + EVs versus MCT + vehicle groups revealed upregulation of proteasome and autophagy pathways in MCT + vehicle, which were attenuated by hMSC‐EV. These results support a promising role for EVs in improving pulmonary vascular remodeling and RV function in PH by modulating signaling pathways involved in proteasome, autophagy, cellular energetic and metabolism.
Related
- Intratracheal Administration of Benzbromarone Attenuates Pulmonary Vascular Remodeling and Improves Survival in Rats with Monocrotaline-Induced Pulmonary Hypertension
- Inhaled nanogels ameliorate vascular remodeling in pulmonary arterial hypertension via normalization of endothelia-smooth muscle cell crosstalk
- Tacrolimus ameliorates pulmonary hypertension associated with pulmonary fibrosis via modulation of vascular remodeling
- Beyond Vasodilation in Pulmonary Arterial Hypertension: Integrating Remodeling-Directed Therapies into Risk-Guided Management
- Right Ventricular Remodeling Using Three-Dimensional Echocardiography in Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: A Case–Control Study
BibTeX
@article{corssac2026hbmmscderived,
title = {{hBM‐MSC‐Derived EVs Improved Pulmonary Vascular Remodeling and Right Ventricle Function in a Mouse Pulmonary Hypertension Model}},
author = {Giana Blume Corssac and Rayane Brinck Teixeira and Vivian Fuguhara and Catherine Karbasiafshar and Olin D. Liang and Frank W. Sellke and Adriane Belló‐Klein and M. Ruhul Abid},
journal = {Pulmonary Circulation},
year = {2026},
month = nov,
doi = {10.1002/pul2.70439},
url = {https://doi.org/10.1002/pul2.70439},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - hBM‐MSC‐Derived EVs Improved Pulmonary Vascular Remodeling and Right Ventricle Function in a Mouse Pulmonary Hypertension Model
AU - Giana Blume Corssac
AU - Rayane Brinck Teixeira
AU - Vivian Fuguhara
AU - Catherine Karbasiafshar
AU - Olin D. Liang
AU - Frank W. Sellke
AU - Adriane Belló‐Klein
AU - M. Ruhul Abid
PY - 2026
DA - 2026/11/12
JO - Pulmonary Circulation
DO - 10.1002/pul2.70439
UR - https://doi.org/10.1002/pul2.70439
AB - Pulmonary hypertension (PH) is characterized by elevated mean pulmonary arterial pressure (mPAP), pulmonary vascular remodeling, and right ventricle (RV) hypertrophy and failure. PH is a rare disease, with significant morbidity and limited therapeutic options. Human Mesenchymal Stem‐cell derived (hMSC) extracellular vesicles (EVs) have shown potential in improving pulmonary artery flow and RV function. The aim of this study was to evaluate the therapeutic effects of hMSC‐EVs in a mouse model of monocrotaline (MCT)‐induced PH. MCT + EVs animals compared to MCT + vehicle alone demonstrated improvement in RV function with an increase in Tricuspid Annular Plane Systolic Excursion by 37.1 ± 2.6% (p = 0.0011) and reduction in RV hypertrophy by 18.6 ± 7.6% (p = 0.0218) using Fulton's index. Pulmonary artery flow, evaluated by echocardiography of pulmonary artery acceleration time, was improved with EV treatment by 18.5 ± 1.3% (p = 0.0419). Histological studies demonstrated a corresponding reduction in pulmonary arteriolar muscularization by 41.2 ± 18.5% (p = 0.0004). Western blot analysis of MCT + EVs versus MCT + vehicle demonstrated modulations in proteins related to metabolism and cellular energetics in lungs and to calcium sequestration in RV. Proteomic analysis of circulating EVs from MCT + EVs versus MCT + vehicle groups revealed upregulation of proteasome and autophagy pathways in MCT + vehicle, which were attenuated by hMSC‐EV. These results support a promising role for EVs in improving pulmonary vascular remodeling and RV function in PH by modulating signaling pathways involved in proteasome, autophagy, cellular energetic and metabolism.
SN - 2045-8932
SN - 2045-8940
ER -